US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Militia Long/Short Equity ETF

37.88

+0.63001.69%

Post-market: 37.880.00000.00%19:30 EDT

Volume:52.02K

Turnover:1.97M

Market Cap:342.44M

PE:- -

High:37.97

Open:37.82

Low:37.60

Close:37.25

52wk High:39.80

52wk Low:30.66

Shares:9.04M

Float Shares:9.04M

Volume Ratio:0.80

T/O Rate:0.58%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients

Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting

Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026

C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population

Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress

MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial

New Partner Emerges for RAS Inhibitors in Treating the "King of Cancers"

Iovance’s Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia

Groundbreaking Cancer Treatment Doubles Survival in Pancreatic Cancer, Cutting Death Risk by 60%

ASCO 2026 | Updated Data from an Oral Presentation of InnoCare's Novel BCL2 Inhibitor Mesutoclax in MDS and AML Released

Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting

BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026

Legend Biotech Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI® Data in Multiple Myeloma at ASCO 2026

NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026

Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO

Ascentage Pharma Presents Its First Dataset on MDM2-p53 Inhibitor Alrizomadlin (APG-115) in Pediatric Solid Tumors at ASCO 2026

Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigershowtime.com/stock/ORR/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"ORR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","market":"US","secType":"STK","nameCN":"Militia Long/Short Equity ETF","latestPrice":37.88,"timestamp":1790971200000,"preClose":37.25,"halted":0,"volume":52018,"hourTrading":{"tag":"盘后","latestPrice":37.88,"preClose":37.88,"latestTime":"19:30 EDT","volume":537,"amount":20341.56,"timestamp":1790983804845,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.016912751677852417,"floatShares":9040000,"shares":9040000,"eps":0,"marketStatus":"Market Closed","change":0.63,"latestTime":"10-02 16:00:00 EDT","open":37.82,"high":37.9699,"low":37.6,"amount":1965631.8915940002,"amplitude":0.00993,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791187200000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":37.25,"sharesOutstanding":12900000,"nav":37.48,"aum":338819200,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":37.88,"preClose":37.88,"latestTime":"19:30 EDT","volume":537,"amount":20341.56,"timestamp":1790983804845,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.798571665918667,"impliedVol":0.202,"impliedVolPercentile":0.7043},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","floatShares":9040000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.798571665918667,"shares":9040000,"dividePrice":0,"high":37.9699,"amplitude":0.00993,"preClose":37.25,"low":37.6,"week52Low":30.655,"pbRate":"--","week52High":39.8,"institutionHeld":0,"latestPrice":37.88,"eps":0,"divideRate":0,"volume":52018,"delay":0,"ttmEps":0,"open":37.82,"prevYearClose":34.16,"prevWeekClose":38.3781,"prevMonthClose":37.77,"prevQuarterClose":37.77,"fiveDayClose":38.3781,"twentyDayClose":39.1754,"sixtyDayClose":36.83},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ORR\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ORR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ORR\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ORR\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2643228204","title":"Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2643228204","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643228204?lang=en_us&edition=fundamental","pubTime":"2026-06-15 07:30","pubTimestamp":1781479800,"startTime":"0","endTime":"0","summary":"Poster presentations from ongoing clinical trials of two core assets, olverembatinib and lisaftoclax, highlight global innovation capabilities in hematologic malignancies ROCKVILLE, Md. and SUZHOU, Ch","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/14/3311475/0/en/Ascentage-Pharma-Presents-Multiple-Clinical-Updates-at-EHA2026-Congress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ORR","PFS","CSF","BK4211","AAPG","BK4195"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643246367","title":"Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2643246367","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643246367?lang=en_us&edition=fundamental","pubTime":"2026-06-14 15:15","pubTimestamp":1781421300,"startTime":"0","endTime":"0","summary":"Achieved 100% ORR and 83.3% CR rate at dose level 2 following a single infusion in patients with relapsed/refractory B-NHL in an ongoing Phase 1 studySingle infusion of LB2501 generated dose-dependent","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/14/3311435/0/en/Legend-Biotech-Establishes-Clinical-Proof-of-Concept-for-LB2501-a-Potential-First-in-Class-In-Vivo-CD19-CD20-Dual-Targeting-CAR-T-in-Relapsed-Refractory-B-Cell-Non-Hodgkin-Lymphoma.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","BK4006","BK4230","LEGN","LU2065731478.USD","BK4187","IE00B7SZL793.SGD","LU0963586101.USD","BK4588","IE0031619046.USD","CR","CAR","CRS","IE00B66KJ199.SGD","BK4022","XBI","BK4161","BK4585","ORR","IRR","BK4505","BK4139","IE00B19Z4B17.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643217815","title":"Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2643217815","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643217815?lang=en_us&edition=fundamental","pubTime":"2026-06-14 00:45","pubTimestamp":1781369100,"startTime":"0","endTime":"0","summary":"Media ReleaseCOPENHAGEN, Denmark; June 13, 2026 Results from the Phase 2 EPCORE DLBCL-3 trial show fixed-duration epcoritamab monotherapy demonstrated early responses in elderly patients with newly di","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/13/3311409/0/en/Genmab-Announces-Epcoritamab-Monotherapy-and-Epcoritamab-Based-Combination-Regimens-Demonstrate-High-Response-Rates-in-Elderly-Patients-with-Newly-Diagnosed-Diffuse-Large-B-Cell-Ly.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4195","CR","IE00B7SZL793.SGD","BK4211","LU0963586101.USD","BK4006","PFS","IE00B19Z4B17.USD","LU2065731478.USD","BK4161","ORR","CRS","IE00B66KJ199.SGD","IE0031619046.USD","BK4187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642238199","title":"Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating  Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2642238199","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642238199?lang=en_us&edition=fundamental","pubTime":"2026-06-11 22:45","pubTimestamp":1781189100,"startTime":"0","endTime":"0","summary":"Media Release COPENHAGEN, Denmark; June 11, 2026 Findings from a post-hoc subgroup analysis of the Phase 3 EPCORE FL-1 trial reinforce fixed-duration epcoritamab in combination with rituximab and lena","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/11/3310630/0/en/Genmab-Presents-EPCORE-FL-1-Subgroup-Data-Demonstrating-Consistent-Efficacy-and-Safety-Results-for-Epcoritamab-in-Combination-with-Rituximab-and-Lenalidomide-R2-Across-Relapsed-or-.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4195","PFS","BK4225","ORR","BK4161","CR","BK4211","HR","BK4203"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642282822","title":"Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2642282822","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642282822?lang=en_us&edition=fundamental","pubTime":"2026-06-11 20:00","pubTimestamp":1781179200,"startTime":"0","endTime":"0","summary":"-- Single dose of CB-011 produced deep, durable responses in heavily pretreated, BCMA-nave patients with r/r MM: 83% CR rate, 91% MRD negativity, and 50% of patients in ≥CR at 15 months -- -- Case stu","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/11/3310377/0/en/Caribou-Biosciences-Reports-Dose-Escalation-Durability-Data-for-CB-011-at-the-2026-European-Hematology-Association-EHA-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314106906.USD","CAR","CRBU","BK4139","IE0031619046.USD","IE00B19Z4B17.USD","LU1506573853.SGD","ALT","LU1878469433.USD","LU0256863811.USD","BK4187","LU2065731478.USD","BK4022","BK4539","LD","LU0868494617.USD","EPV","BK4588","IE00B66KJ199.SGD","IE00B7SZL793.SGD","BK4230","LU0963586101.USD","BK4599","LU0417517546.SGD","ORR","BK4585","BK4107","CRS","BK4559","BK4006"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642289420","title":"Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2642289420","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642289420?lang=en_us&edition=fundamental","pubTime":"2026-06-11 19:03","pubTimestamp":1781175780,"startTime":"0","endTime":"0","summary":"–Real-world study of revumenib shows 82% (9/11) ORR and 64% (7/11) CR/CRh rate among R/R NPM1m or KMT2Ar patients treated with revumenib monotherapy or combinations – –Ph 1 trial of revumenib with int","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/11/3310342/0/en/Syndax-Showcases-Revuforj-revumenib-Clinical-Activity-in-Multiple-Acute-Leukemia-Subtypes-and-Settings-at-EHA-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CR","ORR","LU1699723380.USD","BK4008","LU1571399168.USD","SAVE","LU2355687059.USD","LU1559883803.SGD","BK4107","ECG","BK4129","LU0566484027.USD","BK4500","HSCT","LU0985320562.USD","BK4533","ALL","BK4588","BK4585","BK4161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642289288","title":"C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population","url":"https://stock-news.laohu8.com/highlight/detail?id=2642289288","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642289288?lang=en_us&edition=fundamental","pubTime":"2026-06-11 19:00","pubTimestamp":1781175600,"startTime":"0","endTime":"0","summary":"At the 100 g Recommended Phase 2 Dose (RP2D), Cemsidomide Demonstrated a 53% Overall Response Rate, Including Complete Responses and Minimal Residual Disease (MRD) Negative Status Cemsidomide Was Well","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/11/3310320/0/en/C4-Therapeutics-Presents-Phase-1-Data-at-European-Hematology-Association-EHA-2026-Congress-Highlighting-Cemsidomide-as-a-Potential-Best-in-Class-IKZF1-3-Degrader-for-Multiple-Myelo.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU0289739699.SGD","BK4161","PR","EPV","BK4196","LU1261432733.SGD","IE00B19Z3B42.SGD","LU1059921491.USD","BK4588","ORR","IE00BSNM7G36.USD","CR","IE0002270589.USD","CCCC","BK4213","LU0868494617.USD","LU0058720904.USD","CI","BK4139","IE00B19Z3581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642401957","title":"Cellectis Presents Final Phase 1 Results of Lasme-cel and  Preliminary Results on Eti-cel at EHA 2026 Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2642401957","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642401957?lang=en_us&edition=fundamental","pubTime":"2026-06-11 14:40","pubTimestamp":1781160000,"startTime":"0","endTime":"0","summary":"NEW YORK, June  11, 2026  (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to de","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/11/3310207/0/en/Cellectis-Presents-Final-Phase-1-Results-of-Lasme-cel-and-Preliminary-Results-on-Eti-cel-at-EHA-2026-Congress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLLS","CAR","BK4139","IE0031619046.USD","IE00B19Z4B17.USD","BK4231","BK4161","BK4187","LU2065731478.USD","CR","BK4022","ADC","IE00B66KJ199.SGD","IE00B7SZL793.SGD","BK4230","LU0963586101.USD","ORR","HSCT","CRS","BK4006","BK4080"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642209429","title":"MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2642209429","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642209429?lang=en_us&edition=fundamental","pubTime":"2026-06-10 21:15","pubTimestamp":1781097300,"startTime":"0","endTime":"0","summary":"Additional data from MAIA’s THIO-101 expansion may further support an accelerated approval filing with the FDA Potential breakthrough therapy holds substantial commercial opportunity in a projected $7","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/10/3309785/0/en/MAIA-Biotechnology-Activates-and-Opens-Enrollment-at-Second-U-S-Clinical-Site-for-International-Phase-2-THIO-101-Expansion-Trial.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAIA","LU2487616109.SGD","CPI","BK4081","EMA","LU0210528500.USD","BK4585","BK4107","LU0053666078.USD","L","BK4139","BK4588","ORR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109356337","title":"New Partner Emerges for RAS Inhibitors in Treating the \"King of Cancers\"","url":"https://stock-news.laohu8.com/highlight/detail?id=1109356337","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109356337?lang=en_us&edition=fundamental","pubTime":"2026-06-09 18:21","pubTimestamp":1781000505,"startTime":"0","endTime":"0","summary":"Pancreatic cancer is often referred to as the \"king of cancers.\" This label reflects the harsh reality long faced by patients: rapid disease progression, subtle early symptoms, frequent late-stage...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BD6J9T35.USD","IE00BZ199S13.USD","BK4512","LU2357305700.SGD","LU1720051017.SGD","BK4141","ON","LU1720051108.HKD","BK4605","IE00BFMHRM44.USD","LU1978683503.SGD","BK4195","LU0124384867.USD","LU1854104046.USD","LU1861214812.USD","LU0724618433.USD","LU1861219969.SGD","LU2298322129.HKD","BK4585","LU1861215975.USD","LU1861220033.SGD","BK4588","ORR","LU1548497426.USD","PFS","LU0348723411.USD","LU1854103824.USD","BK4211","LU2360107325.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640184320","title":"Iovance’s Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2640184320","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640184320?lang=en_us&edition=fundamental","pubTime":"2026-06-04 04:05","pubTimestamp":1780517100,"startTime":"0","endTime":"0","summary":"First T cell therapy for a solid tumor cancer and first treatment option approved in Australia for advanced melanoma after anti-PD-1 and targeted therapy  SAN CARLOS, Calif., June  03, 2026  (GLOBE NE","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/03/3306385/0/en/Iovance-s-Amtagvi-lifileucel-Granted-Approval-for-the-Treatment-of-Advanced-Melanoma-in-Australia.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z4B17.USD","BK4139","IE0031619046.USD","AEIS","ORR","LU0757428866.USD","IE00B7SZL793.SGD","IE00B66KJ199.SGD","LU1815336091.USD","IOVA","BK4157","BK4505","TIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119298317","title":"Groundbreaking Cancer Treatment Doubles Survival in Pancreatic Cancer, Cutting Death Risk by 60%","url":"https://stock-news.laohu8.com/highlight/detail?id=1119298317","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119298317?lang=en_us&edition=fundamental","pubTime":"2026-06-03 21:13","pubTimestamp":1780492387,"startTime":"0","endTime":"0","summary":"A historic breakthrough has been achieved in the global treatment of pancreatic cancer.The innovative drug Daraxonrasib, developed by RedMed, has demonstrated in its latest Phase III clinical trial...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1861220033.SGD","BK4585","BK4195","LU1978683503.SGD","LU1861214812.USD","LU1861215975.USD","LU1720051108.HKD","LU0348723411.USD","IE00BD6J9T35.USD","LU0124384867.USD","IE00BZ199S13.USD","LU0724618433.USD","BK4512","LU1854104046.USD","ON","LU1854103824.USD","LU1861219969.SGD","LU2360107325.USD","LU1548497426.USD","BK4605","BK4141","LU2357305700.SGD","IE00BFMHRM44.USD","LU1720051017.SGD","ORR","BK4588","PFS","LU2298322129.HKD","BK4211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640978848","title":"ASCO 2026 | Updated Data from an Oral Presentation of InnoCare's Novel BCL2 Inhibitor Mesutoclax in MDS and AML Released","url":"https://stock-news.laohu8.com/highlight/detail?id=2640978848","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640978848?lang=en_us&edition=fundamental","pubTime":"2026-06-03 10:47","pubTimestamp":1780454820,"startTime":"0","endTime":"0","summary":"BEIJING, June  02, 2026  (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced toda","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/03/3305756/0/en/ASCO-2026-Updated-Data-from-an-Oral-Presentation-of-InnoCare-s-Novel-BCL2-Inhibitor-Mesutoclax-in-MDS-and-AML-Released.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2413666426.HKD","LU1093756325.SGD","BK4548","BK4533","MTD","LU0347712357.USD","IE00BYQQ9H92.USD","BK4588","LU2211817866.USD","IE00B5TLWC47.USD","BK4567","LU2413666699.HKD","LU1093756168.USD","BK4121","BK4161","BK4585","IE00BFXG0V08.USD","ORR","CR","LU1721428933.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640945316","title":"Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2640945316","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640945316?lang=en_us&edition=fundamental","pubTime":"2026-06-02 21:06","pubTimestamp":1780405560,"startTime":"0","endTime":"0","summary":"- The trial achieved its primary goal of selecting the efficacious and safe dose of onvansertib + standard-of-care (SoC) regimen for the registrational program - - 30 mg onvansertib + FOLFIRI/bevacizu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/02/3305287/0/en/Cardiff-Oncology-Announces-Presentation-of-Positive-Results-from-its-Randomized-Controlled-Phase-2-Trial-of-Onvansertib-in-First-Line-RAS-Mutated-mCRC-at-the-2026-ASCO-Annual-Meeti.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4225","BK4161","LU1548497426.USD","LU1854103824.USD","IE00BD6J9T35.USD","BK4195","LU1854104046.USD","LU1861219969.SGD","LU0724618433.USD","ORR","BK4203","IE00BZ199S13.USD","LU0124384867.USD","LU2360107325.USD","IE00BFMHRM44.USD","LU2298322129.HKD","HR","LU1720051108.HKD","LU2357305700.SGD","LU0054578231.USD","LU1861214812.USD","LU1720051017.SGD","BK4211","LU0348723411.USD","BK4605","BK4141","LU1978683503.SGD","PFS","BK4512","LU0053671581.USD","LU1861215975.USD","BK4588","ITT","LU1861220033.SGD","ON"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640175949","title":"BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2640175949","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640175949?lang=en_us&edition=fundamental","pubTime":"2026-06-02 19:00","pubTimestamp":1780398000,"startTime":"0","endTime":"0","summary":"Meaningful clinical benefit: Median PFS at 7.0 months, median DoR is 9.3 months with DCR of 79.5% in metastatic NSCLC patients with acquired resistance to immune checkpoint inhibitorsDurable survival ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/02/3304984/0/en/BeyondSpring-Presents-the-Latest-Update-of-a-Phase-2-Study-Demonstrating-Durable-Clinical-Benefit-of-Pembrolizumab-Plus-Plinabulin-Docetaxel-in-Metastatic-NSCLC-After-Progression-o.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0210528500.USD","BYSI","ADC","LU0053666078.USD","BK4107","BK4211","LU2487616109.SGD","BK4588","PFS","BK4080","BK4195","AR","L","ORR","BK4231","BK4213","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640570849","title":"Legend Biotech Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI® Data in Multiple Myeloma at ASCO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2640570849","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640570849?lang=en_us&edition=fundamental","pubTime":"2026-06-01 22:00","pubTimestamp":1780322400,"startTime":"0","endTime":"0","summary":"LB2102 demonstrated a manageable safety profile and encouraging clinical activity in solid tumors among heavily pretreated patientsResponses observed at higher dose levels of LB2102 with an ORR of 28.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/01/3304508/0/en/Legend-Biotech-Presents-First-in-Human-LB2102-Results-in-Solid-Tumors-and-New-CARVYKTI-Data-in-Multiple-Myeloma-at-ASCO-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","LU1165135440.EUR","LU1596574779.USD","LU1620156213.USD","BK4006","BK4230","LEGN","LU2413666004.HKD","BK4086","LU2065731478.USD","BK4187","IE00B7SZL793.SGD","LU2413665964.HKD","LU0963586101.USD","BK4588","SG9999001440.SGD","IE0031619046.USD","IEC","LU1543694498.USD","MAS","LU0170899867.USD","CAR","CRS","BK4201","IE00B66KJ199.SGD","BK4022","XBI","BK4585","ORR","PML","BK4505","BK4139","IE00B19Z4B17.USD","EC","LU1620156130.USD","LU1721427968.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640951862","title":"NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2640951862","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640951862?lang=en_us&edition=fundamental","pubTime":"2026-06-01 20:00","pubTimestamp":1780315200,"startTime":"0","endTime":"0","summary":"55% ORR in gynecologic cancers with 52.9% in ovarian and 66.7% in USC at 12 weeks by best response per RECIST 1.1 within the therapeutic dose range (4.8 – 8.0 mg/kg)Favorable safety and tolerability i","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/01/3304283/0/en/NextCure-Presents-Positive-SIM0505-Phase-1-Dose-Escalation-Data-in-Patients-with-Gynecologic-Cancers-at-ASCO-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PROC","BK4213","BK4007","PR","RCC","BK4231","KOL","ORR","ADC","BK4080"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640804959","title":"Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO","url":"https://stock-news.laohu8.com/highlight/detail?id=2640804959","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640804959?lang=en_us&edition=fundamental","pubTime":"2026-06-01 19:30","pubTimestamp":1780313400,"startTime":"0","endTime":"0","summary":"- 17.3 months median overall survival in 55 first-line pancreatic cancer patients; vs. 8.5 months for standard of care chemotherapy in the pivotal MPACT study - - Only two categories of Grade 3+ treat","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/01/3304230/0/en/Immuneering-Presents-Compelling-17-3-Month-Median-Overall-Survival-and-Favorable-Tolerability-with-Atebimetinib-Chemotherapy-in-First-Line-Pancreatic-Cancer-Patients-at-ASCO.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR","IMRX","BK4539","BK4139","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640894409","title":"Ascentage Pharma Presents Its First Dataset on MDM2-p53 Inhibitor Alrizomadlin (APG-115) in Pediatric Solid Tumors at ASCO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2640894409","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640894409?lang=en_us&edition=fundamental","pubTime":"2026-06-01 07:30","pubTimestamp":1780270200,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md. and SUZHOU, China, May  31, 2026  (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company e","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/31/3303965/0/en/Ascentage-Pharma-Presents-Its-First-Dataset-on-MDM2-p53-Inhibitor-Alrizomadlin-APG-115-in-Pediatric-Solid-Tumors-at-ASCO-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CDE","LU1223082196.USD","BK4161","LU1223082519.USD","LU1223083913.SGD","LU2125909916.SGD","LU1923622291.USD","CR","BK4139","EWS","LU2125909759.SGD","AAPG","BK4168","ORR","NB","APG","BK4129","BK4017"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639988566","title":"Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2639988566","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639988566?lang=en_us&edition=fundamental","pubTime":"2026-05-31 20:00","pubTimestamp":1780228800,"startTime":"0","endTime":"0","summary":"Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma Brenetafusp monotherapy resulted in a 6-month overall survival rate of 87% and disease con","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/31/3303917/0/en/Immunocore-presents-updated-Phase-1-data-of-brenetafusp-in-patients-with-heavily-pretreated-advanced-melanoma.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00BFXG0V08.USD","BK4107","BK4195","BK4548","MTD","BK4567","LU2413666426.HKD","BK4585","L","PFS","IE00BYQQ9H92.USD","LU1721428933.USD","LU2211817866.USD","LU0053666078.USD","LU2487616109.SGD","CM","BK4121","IE00B5TLWC47.USD","LU1093756168.USD","LU0347712357.USD","BK4207","LU2413666699.HKD","LU1093756325.SGD","BK4533","BK4211","ORR","LU0210528500.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":4,"totalSize":118,"code":"91000000","status":"200"}]}}